{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inborn+Errors+of+Metabolism&page=20", "query": { "condition": "Inborn Errors of Metabolism", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 1605, "total_pages": 161, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inborn+Errors+of+Metabolism&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inborn+Errors+of+Metabolism&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:37:02.203Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01192828", "title": "Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Homocystinuria" ], "interventions": [ { "name": "taurine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "8 Years to 49 Years" }, "enrollment_count": 15, "start_date": "2010-01", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2018-07-09", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 4, "location_summary": "Aurora, Colorado • Durham, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192828" }, { "nct_id": "NCT03840928", "title": "PatientSpot Formerly Known as ArthritisPower", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis", "Ankylosing Spondylitis", "Fibromyalgia", "Gout", "Crohn Disease", "Juvenile Idiopathic Arthritis", "Lupus Erythematosus", "Myositis", "Osteoarthritis", "Osteoporosis", "Psoriasis", "Psoriatic Arthritis", "Scleroderma", "Dermatomyositis", "Inflammatory Bowel Diseases", "Polymyositis", "Axial Spondyloarthritis", "Diffuse Idiopathic Skeletal Hyperostosis", "Polymyalgia Rheumatica", "Giant Cell Arteritis", "Temporal Arteritis", "Wegener", "Relapsing Polychondritis", "Undifferentiated Connective Tissue Disease", "Spinal Cord Injuries", "Alzheimer Disease", "Amyotrophic Lateral Sclerosis", "Ataxia", "Bell Palsy", "Brain Tumor", "Cerebral Aneurysm", "Epilepsy", "Guillain-Barre Syndrome", "Headache", "Head Injury", "Hydrocephalus", "Lumbar Disc Disease", "Meningitis", "Multiple Sclerosis", "Muscular Dystrophy", "Neurocutaneous Syndromes", "Parkinson Disease", "Stroke", "Cluster Headache", "Tension-Type Headache", "Chronic Obstructive Pulmonary Disease", "Asthma", "Lung Cancer", "Cystic Fibrosis", "Sleep Apnea", "Eczema", "Alopecia", "Chronic Inflammation", "Unstable Angina", "Heart Attack", "Heart Failure", "Arrythmia", "Valve Heart Disease", "High Blood Pressure", "Congenital Heart Disease", "Peripheral Arterial Disease", "Diabetes", "Chronic Liver Disease", "Obesity" ], "interventions": [], "intervention_types": [], "sponsor": "Global Healthy Living Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 40000, "start_date": "2015-04-01", "completion_date": "2025-03-01", "has_results": false, "last_update_posted_date": "2023-12-13", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 1, "location_summary": "Upper Nyack, New York", "locations": [ { "city": "Upper Nyack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840928" }, { "nct_id": "NCT03721367", "title": "Chronic Liver Disease in Urea Cycle Disorders", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Urea Cycle Disorder" ], "interventions": [ { "name": "Diagnostic Ultrasound", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "5 Years to 60 Years" }, "enrollment_count": 28, "start_date": "2017-11-29", "completion_date": "2020-06-01", "has_results": true, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03721367" }, { "nct_id": "NCT06092346", "title": "A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "AMPD3, OMIM*102772, AMP Deaminase Deficiency", "AK1, OMIM *103000, Adenylate Kinase Deficiency", "AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency", "TPMT, OMIM *187680, Thoipurines, Poor Metabolism of", "IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11", "APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency", "HPRT1, OMIM *308000 Lesch-Nyhan Disease", "XDH, OMIM *607633, Xanthinuria Type 1", "SLC2A9, OMIM *606142 Hypouricemia", "SLC22A12, OMIM *607096 Hypouricemia", "PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease", "PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity", "AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia", "ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35", "ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency", "PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency", "ADA2, OMIM *607575,Sneddon Syndrome; VAIHS", "CAD, *1140120, Developmental and Epileptic Encephalopathy", "UPB1, OMIM *606673, Beta-ureidopropionase Deficiency", "DPYS, OMIM *613326, Dihydropyrimidinase Deficiency", "DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency", "DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis)", "UMPS, OMIM *613891, Orotic Aciduria", "NT5C3A, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency", "UNG, OMIM *191525, Hyper-IgM Syndrome 5", "AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2", "Purine-Pyrimidine Metabolism", "Metabolic Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "100 Years", "sex": "ALL", "summary": "1 Month to 100 Years" }, "enrollment_count": 999, "start_date": "2023-12-19", "completion_date": "2099-01-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06092346" }, { "nct_id": "NCT00099996", "title": "Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Diseases", "Metabolism, Inborn Errors" ], "interventions": [ { "name": "SCH-58235", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3, "start_date": "2004-12", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00099996" }, { "nct_id": "NCT01858103", "title": "BMN 110 US Expanded Access Program", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Mucopolysaccharidosis IVA", "Morquio A Syndrome", "MPS IVA" ], "interventions": [ { "name": "BMN 110", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioMarin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01858103" }, { "nct_id": "NCT03569020", "title": "The Diet Gout Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gout", "Hyperuricemia" ], "interventions": [ { "name": "Subsidy for food purchases and dietitian education", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-08-07", "completion_date": "2019-07-23", "has_results": true, "last_update_posted_date": "2021-03-30", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 2, "location_summary": "Woodlawn, Maryland • Boston, Massachusetts", "locations": [ { "city": "Woodlawn", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03569020" }, { "nct_id": "NCT01981720", "title": "Extension Study of PRX-102 for up to 60 Months", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "PRX-102 (pegunigalsidase alfa)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Protalix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2014-01-16", "completion_date": "2021-11-09", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 5, "location_summary": "Gainesville, Florida • Iowa City, Iowa • Baltimore, Maryland + 2 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01981720" }, { "nct_id": "NCT00001596", "title": "Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Albinism", "Inborn Errors of Metabolism", "Oculocutaneous Albinism", "Platelet Storage Pool Deficiency", "Pulmonary Fibrosis" ], "interventions": [ { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "William Gahl, M.D.", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2005-09", "completion_date": "2016-05-09", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001596" }, { "nct_id": "NCT02638220", "title": "Cerebrotendinous Xanthomatosis (CTX) Prevalence Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cerebrotendinous Xanthomatosis (CTX)" ], "interventions": [], "intervention_types": [], "sponsor": "Travere Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 442, "start_date": "2015-09", "completion_date": "2021-02-19", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-15T18:37:02.203Z", "location_count": 44, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02638220" } ] }